.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
Healthtrust
Moodys
US Army
QuintilesIMS
Dow
Harvard Business School
Merck
Julphar

Generated: November 19, 2017

DrugPatentWatch Database Preview

Covis Pharma Bv Company Profile

« Back to Dashboard

What is the competitive landscape for COVIS PHARMA BV, and when can generic versions of COVIS PHARMA BV drugs launch?

COVIS PHARMA BV has seven approved drugs.

There are four US patents protecting COVIS PHARMA BV drugs.

There are fifty-four patent family members on COVIS PHARMA BV drugs in twenty countries and five supplementary protection certificates in two countries.

Summary for Covis Pharma Bv

International Patents:54
US Patents:4
Tradenames:8
Ingredients:6
NDAs:7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv
PRILOSEC
omeprazole magnesium
FOR SUSPENSION, DELAYED RELEASE;ORAL022056-001Mar 20, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
BETAPACE AF
sotalol hydrochloride
TABLET;ORAL021151-005Mar 14, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-008Jan 2, 2008ABRXYesYes► Subscribe► Subscribe► Subscribe
Covis Pharma Bv
BETAPACE AF
sotalol hydrochloride
TABLET;ORAL021151-002Feb 22, 2000AB2RXYesNo► Subscribe► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-002Feb 2, 1995DISCNYesNo► Subscribe► Subscribe► Subscribe
Covis Pharma Bv
BETAPACE
sotalol hydrochloride
TABLET;ORAL019865-003Oct 30, 1992AB1RXYesNo► Subscribe► Subscribe► Subscribe
Covis Pharma Bv
BETAPACE AF
sotalol hydrochloride
TABLET;ORAL021151-007Apr 2, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Covis Pharma Bv

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-008Jan 2, 2008► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-005Jan 2, 2008► Subscribe► Subscribe
Covis Pharma Bv
PRILOSEC
omeprazole magnesium
FOR SUSPENSION, DELAYED RELEASE;ORAL022056-001Mar 20, 2008► Subscribe► Subscribe
Covis Pharma Bv
RILUTEK
riluzole
TABLET;ORAL020599-001Dec 12, 1995► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-006Jan 2, 2008► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-001Feb 2, 1995► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-004Feb 2, 1995► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-007Jan 2, 2008► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-005Jan 2, 2008► Subscribe► Subscribe
Covis Pharma Bv
SULAR
nisoldipine
TABLET, EXTENDED RELEASE;ORAL020356-003Feb 2, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for COVIS PHARMA BV drugs

Drugname Dosage Strength Tradename Submissiondate
nisoldipine
Extended-release Tablets8.5 mg and 17 mg
SULAR
3/2/2009
nisoldipine
Extended-release Tablets25.5 mg and 34 mg
SULAR
11/28/2008
nisoldipine
Extended-release Tablets20 mg and 30 mg
SULAR
11/7/2007
nisoldipine
Extended-release Tablets40 mg
SULAR
6/11/2007

Non-Orange Book Patents for Covis Pharma Bv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,679,534HMG-CoA reductase inhibitor extended release formulation► Subscribe
6,440,387 Methods for determining risk of Alzheimer's disease► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Covis Pharma Bv Drugs

Country Document Number Estimated Expiration
Israel142474► Subscribe
Germany10085183► Subscribe
Australia774278► Subscribe
Hong Kong1050134► Subscribe
Sweden9803772► Subscribe
Portugal1124539► Subscribe
Slovenia1124539► Subscribe
Germany20023538► Subscribe
Canada2315329► Subscribe
Germany69832092► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Covis Pharma Bv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/013United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
11/016Ireland► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB01/006United Kingdom► SubscribePRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
12/048Ireland► SubscribePRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cerilliant
Deloitte
Merck
Johnson and Johnson
Cipla
Fuji
US Army
Julphar
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot